Primary care clinicians are called on to care for adolescents in a time with increasing pharmacologic agents that are available in the management of these patients. The emphasis in this book is on the current pharmacologic treatment of common medical disorders in adolescents. Selected topics of practical relevance in adolescent medicine are covered. The goal of this book is to provide a succinct and practical guide specifically written for practicing physicians and allied health professionals who work with adolescents.
Inhaltsverzeichnis
1;Forword;17 2;Contributors;19 3;Abbreviations;21 4;1 Introduction Adolescent medicine: Pharmacotherapeutics in general, mental, and sexual health;27 5;2 Overview on adolescence;35 5.1;2.1 Introduction;35 5.1.1;2.1.1 Terminology;35 5.1.2;2.1.2 Demography of adolescent population;36 5.1.3;2.1.3 Normal adolescent sexuality stages;36 5.1.4;2.1.4 The process of CNS maturation;38 5.2;2.2 Puberty;38 5.3;2.3 Sexual behavior;41 5.3.1;2.3.1 Homosexuality;45 5.3.2;2.3.2 Prevalence;46 5.3.3;2.3.3 Caring for the gay, lesbian, bisexual, and transgendered (GLBT) youth;47 5.3.4;2.3.4 The adolescent sex offender;47 5.4;2.4 Health status of adolescents;47 5.4.1;2.4.1 Mental health;48 5.4.2;2.4.2 Youth violence;49 5.4.3;2.4.3 Mortality;50 5.4.4;2.4.4 Homicide and suicide;50 5.4.5;2.4.5 Motor vehicle accidents;51 5.4.6;2.4.6 Abuse;51 5.4.7;2.4.7 Dating violence;52 5.4.8;2.4.8 Runaway and homeless youth;52 5.5;2.5 Caring for adolescents;53 5.5.1;2.5.1 Involvement of parents;53 5.5.2;2.5.2 Confidentiality;59 5.6;2.6 Immunizations;60 5.7;2.7 Counseling;61 5.8;2.8 Conclusions;61 6;3 Concepts of health care in adolescents in the twenty-first century;65 6.1;3.1 Introduction;65 6.2;3.2 Adolescents: The population;65 6.2.1;3.2.1 Financing of the adolescent population;66 6.2.2;3.2.2 Subgroups of the adolescent population;66 6.2.3;3.2.3 Complexity of the adolescent population;67 6.3;3.3 Use of modern health-ITs;68 6.3.1;3.3.1 Text messaging;68 6.3.2;3.3.2 Internet;68 6.3.3;3.3.3 Multifaceted approaches;69 6.4;3.4 Challenges: Use of modern health-ITs;70 6.4.1;3.4.1 Accuracy and validity of data and data sources;70 6.4.2;3.4.2 Privacy and security responsibilities;70 6.4.3;3.4.3 Health literacy and health-IT literacy;71 6.4.4;3.4.4 Cost and lack of revenue;72 6.5;3.5 Opportunities: Use of modern health-ITs;73 6.5.1;3.5.1 Provider-adolescent engagement at visit;73 6.5.2;3.5.2 Provider-adolescent engagement between visits;73 6.5.3;3.5.3 Provider-provider engagement;75 6.6;3.6 Practicalities: Use of
modern health-ITs;77 6.7;3.7 Conclusions;78 7;4 Principles of pharmacology;81 7.1;4.1 Introduction;81 7.2;4.2 Pharmacokinetics;81 7.2.1;4.2.1 Absorption;81 7.2.2;4.2.2 Distribution;82 7.2.3;4.2.3 Metabolism;83 7.2.4;4.2.4 Excretion;84 7.2.5;4.2.5 Drug dosing and therapeutic drug monitoring;85 7.3;4.3 Pharmacodynamics;86 7.4;4.4 Pharmacogenetics and Pharmacogenomics;87 7.5;4.5 Conclusions;90 8;5 Basic concepts of neurotransmission;93 8.1;5.1 Introduction;93 8.2;5.2 Neurotransmission;93 8.2.1;5.2.1 The neuron;93 8.2.2;5.2.2 The synapse;94 8.2.3;5.2.3 Chemical neurotransmission;95 8.3;5.3 Allosteric modulation;96 8.4;5.4 Nonsynaptic (volume) neurotransmission;96 8.5;5.5 Divergence and covergence;96 8.5.1;5.5.1 Agonists and antagonists;96 8.6;5.6 Major neurotransmitter systems;97 8.6.1;5.6.1 Cholinergic system;97 8.6.2;5.6.2 Dopaminergic system;97 8.6.3;5.6.3 GABAergic system;98 8.6.4;5.6.4 Glutamatergic system;99 8.6.5;5.6.5 Noradrenergic system;99 8.6.6;5.6.6 Serotonergic system;100 8.7;5.7 Conclusions;100 9;6 Genetics and adolescent medicine;105 9.1;6.1 Introduction;105 9.2;6.2 How genetic disease occurs;105 9.3;6.3 Chromosomal inheritance;105 9.4;6.4 Single gene disorders;106 9.5;6.5 Multifactorial inheritance and complex traits;107 9.6;6.6 Other etiologies;109 9.6.1;6.6.1 UPD;109 9.6.2;6.6.2 Imprinting;109 9.6.3;6.6.3 Mitochondrial disorders;109 9.6.4;6.6.4 Syndromes associated with SCD as an example;109 9.6.5;6.6.5 Syndromes associated with the structurally normal heart;110 9.6.6;6.6.6 Syndromes associated with the structural heart disease;110 9.6.7;6.6.7 Factors to be considered regarding the syndromes associated with SCD;111 9.7;6.7 Complex disorders: Behavioral phenotypes as an example;111 9.7.1;6.7.1 Smoking behavior;111 9.7.2;6.7.2 Alcohol and drug use;112 9.7.3;6.7.3 Eating disorders;113 9.8;6.8 Predispositional testing;114 9.9;6.9 Conclusions;115 10;7 Concepts of emergency care;119 10.1;7.1 Introduction;119 10.2;7.2 Advanced cardiac life support (ACLS);120
10.3;7.3 Anaphylaxis;121 10.4;7.4 Asthma;122 10.5;7.5 Conclusions;124 11;8 Concepts of surgical disorders in adolescents;125 11.1;8.1 Introduction;125 11.2;8.2 Abdominal surgery;125 11.2.1;8.2.1 Esophagus;125 11.2.2;8.2.2 Stomach;132 11.2.3;8.2.3 Small bowel;136 11.2.4;8.2.4 Billiary system;147 11.3;8.3 Bariatric surgery;151 11.3.1;8.3.1 Etiology;151 11.3.2;8.3.2 Clinical presentation;151 11.3.3;8.3.3 Workup;151 11.3.4;8.3.4 Treatment;152 11.3.5;8.3.5 Follow-up;154 11.4;8.4 Abdominal wall hernias;154 11.4.1;8.4.1 Etiology;154 11.4.2;8.4.2 Clinical presentation;154 11.4.3;8.4.3 Differential diagnosis;155 11.4.4;8.4.4 Workup;155 11.4.5;8.4.5 Treatment;155 11.4.6;8.4.6 Follow-up;156 11.5;8.5 Breast disease;156 11.5.1;8.5.1 Breast mass;156 11.5.2;8.5.2 Gynecomastia;157 11.6;8.6 Endocrine surgery;158 11.6.1;8.6.1 Thyroid disorders;158 11.6.2;8.6.2 Adrenal tumors;161 11.7;8.7 Skin and soft-tissue lesions;162 11.7.1;8.7.1 Benign skin lesions;162 11.7.2;8.7.2 Malignant lesions;163 11.7.3;8.7.3 STSs;165 11.8;8.8 Conclusions;167 12;9 Concepts of psychotherapy in adolescents;171 12.1;9.1 Introduction;171 12.2;9.2 Definition;171 12.3;9.3 Epidemiology;174 12.3.1;9.3.1 Controversey surrounding the use of evidence-based treatment approaches;175 12.3.2;9.3.2 Obstacles to psychopharmacotherapy;175 12.3.3;9.3.3 Obstacles to psychotherapy;176 12.3.4;9.3.4 Insurance providers;176 12.3.5;9.3.5 Access to therapists;176 12.3.6;9.3.6 Differential diagnosis;177 12.3.7;9.3.7 Treatment modalities used with adolescents;177 12.4;9.4 Management;179 12.5;9.5 Conclusions;179 13;MENTAL HEALTH;181 13.1;10 Substance abuse disorders;183 13.1.1;10.1 Introduction;183 13.1.2;10.2 Alcohol;188 13.1.2.1;10.2.1 Alcohol abuse management;194 13.1.3;10.3 Tobacco;197 13.1.3.1;10.3.1 Management of tobacco abuse;198 13.1.4;10.4 Marijuana;205 13.1.5;10.5 Amphetamines;207 13.1.5.1;10.5.1 Methamphetamine;208 13.1.6;10.6 Cocaine;209 13.1.6.1;10.6.1 Management of cocaine addiction;209 13.1.7;10.7 Opioids;211 13.1.7.1;
10.7.1 Heroin;212 13.1.7.2;10.7.2 Naltrexone;215 13.1.7.3;10.7.3 Methadone;215 13.1.7.4;10.7.4 Buprenorphine;216 13.1.7.5;10.7.5 LAAM;216 13.1.8;10.8 Hallucinogens;216 13.1.9;10.9 MDMA (Ecstasy);217 13.1.10;10.10 Date rape drugs;218 13.1.10.1;10.10.1 Flunitrazepam (Rohypnol);219 13.1.10.2;10.10.2 GHB;219 13.1.10.3;10.10.3 Ketamine;219 13.1.11;10.11 Inhalant drugs;219 13.1.12;10.12 Sedatives;222 13.1.12.1;10.12.1 BZDs;222 13.1.12.2;10.12.2 Barbiturates;222 13.1.13;10.13 Conclusions;223 13.2;11 Pharmacotherapy of adolescent attention deficit/hyperactivity (ADHD) disorder;227 13.2.1;11.1 Introduction;227 13.2.2;11.2 Assessment and treatment principles;228 13.2.2.1;11.2.1 Diagnosis;228 13.2.2.2;11.2.2 Diagnostic workup;228 13.2.2.3;11.2.3 Discussing treatment options, medications, and monitoring with patients and caretakers;228 13.2.3;11.3 Psychopharmacology of ADHD;230 13.2.4;11.4 FDA-approved stimulant agents;231 13.2.4.1;11.4.1 AMP preparations;233 13.2.4.2;11.4.2 Short-acting AMP formulations (about 6 hours duration);233 13.2.4.3;11.4.3 Long-acting AMP formulations (about 810 hours duration);233 13.2.4.4;11.4.4 Prodrug formulation;234 13.2.4.5;11.4.5 MPH preparations;235 13.2.4.6;11.4.6 Oral short-acting MPH formulations (about 35 hours duration);236 13.2.4.7;11.4.7 Oral intermediate-acting MPH formulations (about 8 hours duration);237 13.2.4.8;11.4.8 Long-acting MPH formulations (about 12 hours duration);237 13.2.4.9;11.4.9 MPH transdermal formulation;238 13.2.5;11.5 Special safety considerations regarding stimulants;238 13.2.5.1;11.5.1 Growth;238 13.2.5.2;11.5.2 Tics;239 13.2.5.3;11.5.3 Cardiovascular effects;239 13.2.6;11.6 FDA-approved nonstimulant agents;240 13.2.6.1;11.6.1 Atomoxetine (Strattera);240 13.2.6.2;11.6.2 Guanfacine XR (Intuniv);242 13.2.6.3;11.6.3 Clonidine XR (Kapvay);242 13.2.7;11.7 Non-FDA-approved treatments;243 13.2.8;11.8 General treatment guidelines;243 13.2.8.1;11.8.1 Child versus adolescent symptom presentation;243 13.2.8.2;11.8.2 ADHD and
driving;244 13.2.8.3;11.8.3 Abuse potential;244 13.2.8.4;11.8.4 Differential diagnosis versus comorbidity;244 13.2.8.5;11.8.5 Pretreatment procedures;245 13.2.8.6;11.8.6 Choosing a starting agent;245 13.2.8.7;11.8.7 Short-versus long-acting stimulant formulations;245 13.2.8.8;11.8.8 AMP versus MPH;245 13.2.8.9;11.8.9 Medication titration;246 13.2.8.10;11.8.10 What to do when side effects develop;246 13.2.8.11;11.8.11 Nonimprovement using FDA-approved treatments;246 13.2.8.12;11.8.12 Duration of successful treatment;246 13.2.9;11.9 Summary;247 13.3;12 Disorders of disruption, violence, and cognitive abilities;253 13.3.1;12.1 Introduction;253 13.3.2;12.2 Definitions;253 13.3.2.1;12.2.1 Disruptive behavior disorders;253 13.3.2.2;12.2.2 ODD;253 13.3.2.3;12.2.3 CD;254 13.3.2.4;12.2.4 Developmental disorders (DDs);254 13.3.2.5;12.2.5 Aggression and violence;254 13.3.3;12.3 Epidemiology;255 13.3.4;12.4 Differential diagnosis;256 13.3.4.1;12.4.1 SUDs;256 13.3.4.2;12.4.2 GMCs;258 13.3.4.3;12.4.3 Psychiatric disorders;259 13.3.4.4;12.4.4 DDs;260 13.3.5;12.5 Management;261 13.3.5.1;12.5.1 SUDs;262 13.3.5.2;12.5.2 GMCs;262 13.3.5.3;12.5.3 Psychiatric disorders;263 13.3.5.4;12.5.4 DDs;264 13.3.6;12.6 Summary;264 13.4;13 Mood disorders;269 13.4.1;13.1 Introduction;269 13.4.2;13.2 Epidemiology;269 13.4.3;13.3 Differential diagnosis;271 13.4.4;13.4 Management;271 13.4.4.1;13.4.1 Depressive disorders;271 13.4.4.2;13.4.2 BDs;274 13.4.4.3;13.4.3 Mood disorder NOS;278 13.4.5;13.5 Conclusion;278 13.5;14 Anxiety disorders;281 13.5.1;14.1 Introduction;281 13.5.1.1;14.1.1 SAD;281 13.5.1.2;14.1.2 Panic disorder;282 13.5.1.3;14.1.3 GAD;282 13.5.1.4;14.1.4 Social anxiety disorder;283 13.5.1.5;14.1.5 OCD;283 13.5.1.6;14.1.6 Specific phobia;283 13.5.2;14.2 Epidemiology;284 13.5.3;14.3 Differential diagnosis;284 13.5.4;14.4 Management;285 13.5.4.1;14.4.1 Role of parents;285 13.5.4.2;14.4.2 Role of teachers;285 13.5.4.3;14.4.3 Psychotherapy;286 13.5.4.4;14.4.4 Pharmacotherapy;286 13.5.4.5;14.4.5
SSRIs;286 13.5.4.6;14.4.6 Other agents;288 13.5.4.7;14.4.7 Treatment of comorbidities;290 13.5.5;14.5 Conclusions;291 13.6;15 Schizophrenia;295 13.6.1;15.1 Introduction;295 13.6.1.1;15.1.1 Delusions;296 13.6.1.2;15.1.2 Hallucinations;296 13.6.1.3;15.1.3 Disorganized speech;296 13.6.1.4;15.1.4 Disorganized behavior;296 13.6.1.5;15.1.5 Negative symptoms;296 13.6.2;15.2 Diagnosis;296 13.6.2.1;15.2.1 Premorbid symptoms;297 13.6.3;15.3 Epidemiology;297 13.6.4;15.4 Differential diagnosis;298 13.6.4.1;15.4.1 Substance use disorders (SUDs) and drug intoxications;298 13.6.4.2;15.4.2 Bipolar disorder (BD);299 13.6.4.3;15.4.3 Anxiety disorder;300 13.6.5;15.5 Treatment;300 13.6.5.1;15.5.1 Consultations;300 13.6.5.2;15.5.2 Atypical antipsychotics;302 13.6.5.3;15.5.3 Clozapine;303 13.6.5.4;15.5.4 Typical antipsychotics;303 13.6.5.5;15.5.5 Psychosocial interventions;305 13.6.6;15.6 Conclusions;305 14;SEXUAL AND GYNECOLOGIC HEALTH;309 14.1;16 The adolescent breast;311 14.1.1;16.1 Introduction;311 14.1.2;16.2 Clinicians breast examination;311 14.1.3;16.3 Congenital anomalies;312 14.1.3.1;16.3.1 Athelia and amastia;312 14.1.3.2;16.3.2 Polythelia and polymastia;312 14.1.3.3;16.3.3 Other nipple anomalies;312 14.1.4;16.4 Asymmetric breast development;313 14.1.5;16.5 Underdeveloped breasts;313 14.1.5.1;16.5.1 Tuberous breasts;314 14.1.6;16.6 Virginal hypertrophy;314 14.1.7;16.7 Breast masses;314 14.1.7.1;16.7.1 Cystosarcoma phylloides;316 14.1.7.2;16.7.2 Cystic breast disease;317 14.1.7.3;16.7.3 Fibrocystic change;318 14.1.8;16.8 Nipple discharge;319 14.1.9;16.9 Summary;324 14.2;17 Menstrual disorders in the adolescent female;327 14.2.1;17.1 Introduction;327 14.2.1.1;17.1.1 Adolescent menstrual patterns;327 14.2.2;17.2 Amenorrhea;328 14.2.2.1;17.2.1 Amenorrhea in adolescent athletes;334 14.2.2.2;17.2.2 Management of amenorrhea;335 14.2.2.3;17.2.3 Management of PCOS;336 14.2.2.4;17.2.4 DUB;337 14.2.2.5;17.2.5 DUB management;340 14.2.2.6;17.2.6 Absence of anemia or mild anemia;340 14.2.2.
7;17.2.7 Moderate anemia;341 14.2.2.8;17.2.8 Management of DUB due to coagulation disorders;342 14.2.2.9;17.2.9 Other DUB management options;343 14.2.3;17.3 Dysmenorrhea;343 14.2.3.1;17.3.1 Etiology;345 14.2.3.2;17.3.2 Primary dysmenorrhea management;345 14.2.3.3;17.3.3 Secondary dysmenorrhea;347 14.2.4;17.4 Endometriosis;348 14.2.4.1;17.4.1 Symptomatology;348 14.2.4.2;17.4.2 Diagnosis;349 14.2.4.3;17.4.3 Management of endometriosis;351 14.2.5;17.5 PMS;352 14.2.5.1;17.5.1 Management of PMS;354 14.2.6;17.6 Summary;355 14.3;18 Sexually transmitted diseases (STDs);357 14.3.1;18.1 Introduction;357 14.3.2;18.2 C. trachomatis;360 14.3.3;18.3 Cervicitis;361 14.3.4;18.4 Urethritis and epididymitis;362 14.3.5;18.5 N. gonorrhoeae;362 14.3.6;18.6 PID;363 14.3.7;18.7 Fitz-Hugh-Curtis syndrome;366 14.3.8;18.8 DGI;366 14.3.9;18.9 HSV;367 14.3.10;18.10 T. vaginalis;369 14.3.11;18.11 BV;370 14.3.12;18.12 HPV;371 14.3.13;18.13 Vulvovaginitis;374 14.3.14;18.14 Physiological leukorrhea;375 14.3.15;18.15 C. albicans;375 14.3.16;18.16 Miscellaneous STDs;377 14.3.17;18.17 Homosexuality and STDs in adolescents;380 14.3.17.1;18.17.1 HIV/AIDS;380 14.3.18;18.18 Conclusions;385 14.4;19 Contraception in adolescents;387 14.4.1;19.1 Introduction;387 14.4.2;19.2 Oral contraceptives (OCPs; combined oral contraceptives [COCs]);390 14.4.2.1;19.2.1 Contraindications to OCPs/COCs;393 14.4.2.2;19.2.2 Cardiovascular risks and OCPs;395 14.4.2.3;19.2.3 OCPs and miscellaneous risks;396 14.4.3;19.3 Transdermal hormonal contraception;396 14.4.4;19.4 NuvaRing vaginal ring;397 14.4.5;19.5 POPs;397 14.4.6;19.6 ECs;397 14.4.7;19.7 Injectable contraceptives;398 14.4.8;19.8 IUD;400 14.4.9;19.9 Barrier methods;401 14.4.9.1;19.9.1 Diaphragm and vaginal spermicides;401 14.4.9.2;19.9.2 Cervical cap;402 14.4.9.3;19.9.3 Vaginal contraceptive sponge;403 14.4.9.4;19.9.4 Female condom;403 14.4.9.5;19.9.5 Male condom;403 14.4.10;19.10 Summary;403 14.4.11;19.11 Internet sites;403 14.5;20 Adolescent pregnancy;413 14.5.1;20.1
Introduction;413 14.5.2;20.2 Risks of adolescent pregnancy;415 14.5.3;20.3 Risks for children of adolescents;418 14.5.4;20.4 Adolescent fathers;420 14.5.5;20.5 Abortion;420 14.5.6;20.6 Prevention of adolescent pregnancy and pregnancy complications;420 14.5.7;20.7 Mental health;421 14.5.8;20.8 Conclusions;422 15;ACKNOWLEDGMENTS;425 15.1;21 About the editors;427 15.2;22 About the Department of Pediatrics and Human Development, Michigan State University College of Human Medicine, Michigan State University/Kalamazoo Center for Medical Studies, Kalamazoo, Michigan, United States;429 15.3;23 About the Division of Adolescent Medicine at the University of Kentucky, Lexington, Kentucky, United States;431 15.4;24 About the National Institute of Child Health and Human Development in Israel;433 16;Index;437